...
【24h】

TERLIPRESSIN IN CATECHOLAMINE-RESISTANT SEPTIC SHOCK PATIENTS.

机译:在CATECHOLAMINE-RESISTANT TERLIPRESSIN感染性休克病人。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To determine the effects on hemodynamics, laboratory parameters, and renal function of terlipressin used in septic-shock patients with hypotension not responsive to high-dose norepinephrine (>2.0 microg . kg . min) and dopamine (25 microg . kg . min), a prospective, open-label study was carried out in 17 patients. Patients received one or two boluses of 1 mg of terlipressin. In all patients terlipressin induced a significant increase in mean arterial pressure (MAP), systemic vascular resistance, pulmonary vascular resistance, and left and right ventricular stroke work. The increase in MAP was accompanied by a significant decrease in heart rate and cardiac index, but stroke volume remained unchanged. Oxygen delivery and consumption were significantly decreased. Blood lactate concentrations significantly decreased over the study period. Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were significantly increased. Thrombocytes were significantly decreased. No change in prothrombin time was observed. Renal function, assessed by urine flow and creatinine clearance, was significantly improved. Pulmonary function assessed by Pao2/Fio2 ratio was not affected. A significant reduction in norepinephrine and dopamine infusion rates was observed in all patients. Eight patients died during their ICU stay from late multiple organ failure. Within the limitations of the present study (open-label design, small group of patients), it can be concluded that in septic shock patients with hypotension nonresponsive to fluid resuscitation and high-dose vasopressors, terlipressin can be effective to restore MAP. Cardiac index should be closely monitored because it was significantly decreased by terlipressin. Renal function was significantly improved. Mesenteric circulation was not evaluated, but hepatic function was altered during the study period. Further studies are required to determine whether terlipressin is safe in terms of outcome in septic shock patients.
机译:确定对血流动力学的影响,实验室参数,和肾的功能terlipressin用于感染性休克患者低血压不适应高剂量去甲肾上腺素(> 2.0 microg。多巴胺(25 microg。开放研究进行了17个病人。患者接受一个或两个丸1毫克terlipressin。诱导显著增加意味着动脉压力(MAP),全身血管阻力,肺血管阻力,左和右心室搏出功。伴随着心中明显降低体积率和心脏指数,但中风保持不变。消费明显减少。乳酸浓度显著下降在研究期间。转氨酶(AST)、丙氨酸转氨酶(ALT)明显增加了。降低了。观察到。和肌酐清除率,明显改善。Pao2 /供给率没有影响。减少注入去甲肾上腺素和多巴胺在所有的病人。病人在ICU停留死于晚了多器官功能衰竭。目前的研究(开放性设计,小组的患者),它可以得出结论,在感染性休克低血压患者停止响应液体复苏和高剂量升压,terlipressin可以有效恢复地图。应密切监测,因为心脏指数它被terlipressin显著下降。肾功能明显改善。肠系膜血液循环不评价,但是在研究肝脏功能改变时期。terlipressin是否安全的结果在脓毒性休克患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号